Literature DB >> 31653480

Molecular Basis of Opioid Action: From Structures to New Leads.

Aashish Manglik1.   

Abstract

Since the isolation of morphine from the opium poppy over 200 years ago, the molecular basis of opioid action has remained the subject of intense inquiry. The identification of specific receptors responsible for opioid function and the discovery of many chemically diverse molecules with unique opioid-like efficacies have provided glimpses into the molecular logic of opioid action. Recent revolutions in the structural biology of transmembrane proteins have, for the first time, yielded high-resolution views into the 3-dimensional shapes of all 4 opioid receptors. These studies have begun to decode the chemical logic that enables opioids to specifically bind and activate their receptor targets. A combination of spectroscopic experiments and computational simulations has provided a view into the molecular movements of the opioid receptors, which itself gives rise to the complex opioid pharmacology observed at the cellular and behavioral levels. Further diversity in opioid receptor structure is driven by both genetic variation and receptor oligomerization. These insights have enabled computational drug discovery efforts, with some evidence of success in the design of completely novel opioids with unique efficacies. The combined progress over the past few years provides hope for new, efficacious opioids devoid of the side effects that have made them the scourge of humanity for millennia.
Copyright © 2019 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Analgesic; DOP; G protein–coupled receptor; KOP; MOP; Opioid; Opioid receptor

Mesh:

Substances:

Year:  2019        PMID: 31653480      PMCID: PMC6898784          DOI: 10.1016/j.biopsych.2019.08.028

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  88 in total

1.  Selectivity of mu-opioid receptor determined by interfacial residues near third extracellular loop.

Authors:  G Bonner; F Meng; H Akil
Journal:  Eur J Pharmacol       Date:  2000-09-01       Impact factor: 4.432

Review 2.  Are mu-opioid receptor polymorphisms important for clinical opioid therapy?

Authors:  Jörn Lötsch; Gerd Geisslinger
Journal:  Trends Mol Med       Date:  2005-02       Impact factor: 11.951

3.  Structure-activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain.

Authors:  Xiao-Tao Chen; Philip Pitis; Guodong Liu; Catherine Yuan; Dimitar Gotchev; Conrad L Cowan; David H Rominger; Michael Koblish; Scott M Dewire; Aimee L Crombie; Jonathan D Violin; Dennis S Yamashita
Journal:  J Med Chem       Date:  2013-10-14       Impact factor: 7.446

Review 4.  PAM-Antagonists: A Better Way to Block Pathological Receptor Signaling?

Authors:  Terry Kenakin; Ryan T Strachan
Journal:  Trends Pharmacol Sci       Date:  2018-06-07       Impact factor: 14.819

Review 5.  GPCR Dynamics: Structures in Motion.

Authors:  Naomi R Latorraca; A J Venkatakrishnan; Ron O Dror
Journal:  Chem Rev       Date:  2016-09-13       Impact factor: 60.622

Review 6.  Nanobody stabilization of G protein-coupled receptor conformational states.

Authors:  Jan Steyaert; Brian K Kobilka
Journal:  Curr Opin Struct Biol       Date:  2011-07-21       Impact factor: 6.809

7.  Variation in the mu-opioid receptor gene (OPRM1) is associated with dispositional and neural sensitivity to social rejection.

Authors:  Baldwin M Way; Shelley E Taylor; Naomi I Eisenberger
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-14       Impact factor: 11.205

8.  Functional characterization of human variants of the mu-opioid receptor gene.

Authors:  Ajay Ravindranathan; Geoff Joslyn; Margaret Robertson; Marc A Schuckit; Jennifer L Whistler; Raymond L White
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-15       Impact factor: 11.205

9.  Structure of the human κ-opioid receptor in complex with JDTic.

Authors:  Huixian Wu; Daniel Wacker; Mauro Mileni; Vsevolod Katritch; Gye Won Han; Eyal Vardy; Wei Liu; Aaron A Thompson; Xi-Ping Huang; F Ivy Carroll; S Wayne Mascarella; Richard B Westkaemper; Philip D Mosier; Bryan L Roth; Vadim Cherezov; Raymond C Stevens
Journal:  Nature       Date:  2012-03-21       Impact factor: 49.962

10.  Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic.

Authors:  Aaron A Thompson; Wei Liu; Eugene Chun; Vsevolod Katritch; Huixian Wu; Eyal Vardy; Xi-Ping Huang; Claudio Trapella; Remo Guerrini; Girolamo Calo; Bryan L Roth; Vadim Cherezov; Raymond C Stevens
Journal:  Nature       Date:  2012-05-16       Impact factor: 49.962

View more
  9 in total

1.  The quest for high-resolution G protein-coupled receptor-G protein structures.

Authors:  Reinhard Grisshammer
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-16       Impact factor: 11.205

Review 2.  Recent Molecular Insights into Agonist-specific Binding to the Mu-Opioid Receptor.

Authors:  Ferenc Zádor; Kornél Király; Nariman Essmat; Mahmoud Al-Khrasani
Journal:  Front Mol Biosci       Date:  2022-06-13

Review 3.  Neurochemistry of the Kölliker-Fuse nucleus from a respiratory perspective.

Authors:  Adrienn G Varga; Sebastian N Maletz; Jordan T Bateman; Brandon T Reid; Erica S Levitt
Journal:  J Neurochem       Date:  2020-06-10       Impact factor: 5.546

4.  Cyclizing Painkillers: Development of Backbone-Cyclic TAPS Analogs.

Authors:  Alaa Talhami; Avi Swed; Shmuel Hess; Oded Ovadia; Sarit Greenberg; Adi Schumacher-Klinger; David Rosenthal; Deborah E Shalev; Mattan Hurevich; Philip Lazarovici; Amnon Hoffman; Chaim Gilon
Journal:  Front Chem       Date:  2020-11-12       Impact factor: 5.221

Review 5.  Spoken and Unspoken Matters Regarding the Use of Opioids in Cancer.

Authors:  Janna Baker Rogers; Gerald M Higa
Journal:  J Pain Res       Date:  2022-04-05       Impact factor: 3.133

Review 6.  Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson's Disease.

Authors:  Carla Ferreira; Catarina Almeida; Sandra Tenreiro; Alexandre Quintas
Journal:  Life (Basel)       Date:  2020-06-11

Review 7.  Development of Diphenethylamines as Selective Kappa Opioid Receptor Ligands and Their Pharmacological Activities.

Authors:  Helmut Schmidhammer; Filippo Erli; Elena Guerrieri; Mariana Spetea
Journal:  Molecules       Date:  2020-11-02       Impact factor: 4.411

8.  Antinociceptive Efficacy of the µ-Opioid/Nociceptin Peptide-Based Hybrid KGNOP1 in Inflammatory Pain without Rewarding Effects in Mice: An Experimental Assessment and Molecular Docking.

Authors:  Maria Dumitrascuta; Marcel Bermudez; Olga Trovato; Jolien De Neve; Steven Ballet; Gerhard Wolber; Mariana Spetea
Journal:  Molecules       Date:  2021-05-28       Impact factor: 4.411

Review 9.  Recent Chemical and Pharmacological Developments on 14-Oxygenated-N-methylmorphinan-6-ones.

Authors:  Mariana Spetea; Helmut Schmidhammer
Journal:  Molecules       Date:  2021-09-18       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.